{"FirstGroup": "Introduction", "FirstViewport": {"Zoom": 9.49869494554826, "Pan": [0.674933608170274, 0.8066237510950417]}, "Images": [{"Name": "i0", "Description": "Ovarian Cancer with Annotation - LSP15343", "Path": "https://s3.amazonaws.com/www.cycif.org/gray-stic-1", "Width": 43262, "Height": 27936, "MaxLevel": 6}], "Header": "This sample was taken from a BRCA1 mutant patient (female, age 71 years) who underwent a risk reduction surgery to remove the ovaries and fallopian tubes (bilateral salpingo-oophorectomy; BSO). The patient had a history of bilateral breast cancer, twice previously.\n\nUpon surgery, the patient was diagnosed with Stage 1C High-Grade Serous Ovarian Carcinoma (HGSOC). A 6 mm tumor was found in her right fallopian tube, along with pre-cancerous lesions, including p53 signatures, serous tubal intraepithelial lesions (STIL), and serous tubal intraepithelial carcinoma (STIC). The tumor was found only in fallopian tube. Therefore, there was no involvement in the ovary.    \n\n--\n\n# Metadata about this sample  \n\n### Diagnosis  \n**Age at diagnosis:**  71  \n**Primary diagnosis:**  HGSOC  \n**Surgery type:** bilateral salpingo-oophorectomy (BSO)  \n**Stage at diagnosis:** IC  \n**Fallopian involvement:**  Yes; Right FT (STIC, 6 mm HGSOC)  \n**Ovarian involvement:** No  \n**Genetic features:** BRCA1-mutant  \n**Molecular features:** p53- mutant  \n**Metastatic sites:** None  \n\n### Demographics  \n**Species:** Human  \n**Sex:** Female  \n**Race:** White  \n**Ethnicity:** Non-hispanic or latino  \n**Age at Surgery:** 71 years  \n**Vital status at last follow-up:** Alive. Started Anastrozole and Olaparib in 2021 and 2022, respectively -present  \n**Age at last follow-up:** 73 \n\n### Clinical history\n**Cancer history:** Yes - two prior grade 3 breast cancers  \n**Prior therapeutic agents:** Chemotherapy  \n**Surgical history:** Bilateral mastectomy  \n\n### Therapy\n**Treatment type:** Post-surgical chemotherapy  \n**Therapeutic agents:** Carboplatin and Taxol (Chemotherapeutic agents), Anastrozole and Olaparib. \n\n### Imaging  \n**Imaging Assay Type:** t-CyCIF  \n**Fixative Type:** FFPE  \n**Microscope:** RareCyte CyteFinder 46  \n**Objective:** 20x /0.75 NA  \n**Binned:** Yes  \n\n### Attribution  \n**Please cite this Minerva Story as:**  \nKader, Tanjina, Lin, Jia-Ren and Coy, Shannon. Ovarian Cancer with Annotation - LSP15343. Harvard Tissue Atlas. V1, 2023, [https://www.cycif.org/data/gray-stic-1](https://www.cycif.org/data/gray-stic-1).  \n\n### Sample Identifiers  \n|ID Type |\tID |\n|--|--|\n|**LSP Slide ID:**  |\tLSP15343 |\n| **UPenn ID:**  | Case ID RD-23-005 |  \n\n--", "Rotation": 0, "Layout": {"Grid": [["i0"]]}, "Stories": [{"Name": "", "Description": "", "Waypoints": [{"Name": "Orientation of the sample", "Description": "*Please note that this sample represents several disconnected segments of tissue.*\n\nWe have labeled different regions of the tissue, namely the p53 signatures (arrow heads), STIL (arrow heads) and STIC (white box) (precancerous lesions), and Invasive cancer (arrow heads). In this specimen, we do not have any normal fallopian tube. \n\n", "Arrows": [{"Text": "Invasive Cancer", "HideArrow": false, "Point": [0.7795323447250431, 0.613138778180975], "Angle": 60}, {"Text": "Invasive cancer", "HideArrow": false, "Point": [0.7264514878062631, 0.4783186606391234], "Angle": 240}, {"Text": "Invasive cancer", "HideArrow": false, "Point": [0.02482504547461739, 0.7551176886052435], "Angle": 234}, {"Text": "p53 signature", "HideArrow": false, "Point": [0.22931441725962784, 0.8203255924721597], "Angle": 60}, {"Text": "STIL", "HideArrow": true, "Point": [1.3237010101211784, 0.43893870537632346], "Angle": 60}], "Overlays": [{"x": 0.6642730204294856, "y": 0.7809825552835425, "width": 0.04149957387667569, "height": 0.04869280801930287}, {"x": 1.2617047539845905, "y": 0.38889785719602654, "width": 0.14917977348698597, "height": 0.10022294087953332}], "Group": "Tumor", "Masks": [], "ActiveMasks": [], "Zoom": 0.5187258911132813, "Pan": [0.6010808695895463, 0.5299717934674614]}, {"Name": "Invasive cancer and pre-cancerous lesion STIC", "Description": "The tumor was positive for a TP53 mutation. Most Serous tubal intraepithelial carcinoma (STIC) and HGSOC harbor TP53 mutation. \n\nThis ovarian cancer is thought to have originated from the secretory cells of the fallopian tube, meaning that secretory cells harboring the TP53 mutation may have expanded and proliferated into the tumor. These are called \"p53 signatures\". The signatures preserve the epithelial layer, leaving it intact, then with time, the p53-positive cells expand and start to grow abruptly. \n\nThese growths are known as serous tubal intraepithelial lesions (STIL). STIL was identified in the sample (white box on right hand side). Note that this STIL region still shows some cell polarity.\n\nEventually, STIL is thought to progress to Serous tubal intraepithelial carcinoma (STIC).\n\nSTIC arises in the distal fimbriated end of the fallopian tube and likely represents a precursor lesion to high-grade serous ovarian cancer (HGSOC). The small white box represents one STIC lesion, located next to the carcinoma (arrows and large white box). ", "Arrows": [{"Text": "Invasive Cancer", "HideArrow": false, "Point": [0.7795323447250431, 0.613138778180975], "Angle": 60}, {"Text": "Invasive cancer", "HideArrow": false, "Point": [0.7264514878062631, 0.4783186606391234], "Angle": 240}, {"Text": "Invasive cancer", "HideArrow": false, "Point": [0.02482504547461739, 0.7551176886052435], "Angle": 234}, {"Text": "p53 signature", "HideArrow": false, "Point": [0.22931441725962784, 0.8203255924721597], "Angle": 60}, {"Text": "STIL", "HideArrow": true, "Point": [1.3237010101211784, 0.43893870537632346], "Angle": 60}], "Overlays": [{"x": 0.8513275273561342, "y": 0.46492483346111957, "width": 0.16419032435289005, "height": 0.20989279031950425}, {"x": 0.6642730204294856, "y": 0.7809825552835425, "width": 0.04149957387667569, "height": 0.04869280801930287}, {"x": 1.2617047539845905, "y": 0.38889785719602654, "width": 0.14917977348698597, "height": 0.10022294087953332}], "Group": "Introduction", "Masks": [], "ActiveMasks": [], "Zoom": 0.48282493368700263, "Pan": [0.6120001141521602, 0.5290783665454134]}, {"Name": "Precancer lesion STIC ", "Description": "The epithelial compartment of STIC is shown here as PanCK-positive. CD8-positive cytotoxic T cells are also shown, mainly in the STIC-stromal boundary. Dendritic cells (CD11c-positive) are expected to present antigens to T cells within the STIC-stroma vicinity. ", "Arrows": [], "Overlays": [], "Group": "STIC", "Masks": [], "ActiveMasks": [], "Zoom": 17.49869494554826, "Pan": [0.674933608170274, 0.8066237510950417]}, {"Name": "Tumor", "Description": "Epithelial cells of the tumor cells are shown here as PanCK-positive cells. \n\nYou can observe that two different tumor clones have different expressions of PanCK. ", "Arrows": [{"Text": "Tumor clone 1 with low PanCK expression", "HideArrow": false, "Point": [0.8921557581752497, 0.4982120518163963], "Angle": 227}, {"Text": "Tumor clone 2 with a high PanCK expression", "HideArrow": false, "Point": [0.9730756139202767, 0.6340261972574613], "Angle": 60}], "Overlays": [], "Group": "Tumor", "Masks": [], "ActiveMasks": [], "Zoom": 1.201422938992042, "Pan": [0.7669667131033173, 0.6122005997003653]}, {"Name": "Immune cells in Tumor", "Description": "There are some T cells trafficking in the tumor-stroma boundary. Most of these are tissue resident memory (TRM) T cells. ", "Arrows": [{"Text": "Tumor-Stroma boundary", "HideArrow": false, "Point": [0.9637681816248195, 0.5603849672044328], "Angle": 60}, {"Text": "Tumor clone 1 with a high PanCK expression", "HideArrow": false, "Point": [0.9713086295288256, 0.628632954823865], "Angle": 60}, {"Text": "Tumor clone 2 with a low PanCK expression", "HideArrow": false, "Point": [0.8888381256021378, 0.5126828148669319], "Angle": 235}], "Overlays": [], "Group": "Immune_Tumor", "Masks": [], "ActiveMasks": [], "Zoom": 4.0696371748690146, "Pan": [0.907473282874857, 0.5524786364699263]}, {"Name": "Tissue resident memory T cells  in Tumor", "Description": "However, these TRM show T cell dysfunction. Most TRM that reside in the tumor centre become activated, as indicated by PD1-positivity. \n\nBut some are positive for LAG3, a T cell dysfunction marker. These data suggest that TRM may be spontaneously activated with the exposure of tumor antigen but might be progressing towards exhaustion. Here, few TRM express CD103 and LAG3 (arrows).", "Arrows": [{"Text": "", "HideArrow": false, "Point": [0.9237827535472505, 0.6110365430339685], "Angle": 60}, {"Text": "", "HideArrow": false, "Point": [0.9298393998064889, 0.6075756030561137], "Angle": 60}], "Overlays": [], "Group": "TRM in tumor", "Masks": [], "ActiveMasks": [], "Zoom": 62.87370390978558, "Pan": [0.9252442323116898, 0.6088318398075496]}, {"Name": "Macrophage", "Description": "Apart from TRM in the tumor centre, there are dendritic cells (CD11c-positive) and M2 macrophages (CD163-positive). If these markers co-localize, the cells are macrophages.  ", "Arrows": [], "Overlays": [{"x": 0.9285946542939689, "y": 0.5892197174052675, "width": 0.009111216356460394, "height": 0.0070113203226293}], "Group": "Other immune cells", "Masks": [], "ActiveMasks": [], "Zoom": 44.645062686676546, "Pan": [0.9317211659638278, 0.5923812279245992]}]}], "Channels": [{"Rendered": false, "Name": "DNA", "Path": "DNA-0_4__DNA"}, {"Rendered": false, "Name": "CD103", "Path": "CD103-0_20__CD103"}, {"Rendered": false, "Name": "LAG3", "Path": "LAG3_27__LAG3"}, {"Rendered": false, "Name": "PD1", "Path": "PD1_24__PD1"}, {"Rendered": false, "Name": "CD8a", "Path": "CD8a_11__CD8a"}, {"Rendered": false, "Name": "CD103", "Path": "CD103-0_20__CD103"}, {"Rendered": false, "Name": "PanCK", "Path": "PanCK_10__PanCK"}, {"Rendered": false, "Name": "CD11c", "Path": "CD11c_43__CD11c"}, {"Rendered": false, "Name": "DNA", "Path": "DNA-0_4__DNA"}, {"Rendered": false, "Name": "CD163", "Path": "CD163_36__CD163"}, {"Rendered": false, "Name": "p53", "Path": "p53_7__p53"}], "Groups": [{"Name": "TRM in tumor", "Colors": ["ffffff", "2aa52a", "ff00ff", "0000ff"], "Channels": ["DNA", "CD103", "LAG3", "PD1"], "Descriptions": ["Hoechst", "Tissue resident memory T cells", "", ""]}, {"Name": "Immune_Tumor", "Colors": ["ffffff", "ff00ff", "00ffff"], "Channels": ["DNA", "CD8a", "CD103"], "Descriptions": ["Hoechst", "Cytotoxic T cells", "Tissue resident memory T cells"]}, {"Name": "Tumor", "Colors": ["ffffff", "ff8300"], "Channels": ["DNA", "PanCK"], "Descriptions": ["Hoechst", "epithelial marker"]}, {"Name": "STIC", "Colors": ["ffffff", "ff00ff", "ff8300", "00ffff"], "Channels": ["DNA", "CD8a", "PanCK", "CD11c"], "Descriptions": ["Hoechst", "Cytotoxic T cells", "epithelial marker", "Dendritic cells if CD69 and CD163 negative"]}, {"Name": "Other immune cells", "Colors": ["ffffff", "00ffff", "ff00ff"], "Channels": ["DNA", "CD11c", "CD163"], "Descriptions": ["Hoechst", "Dendritic cells if CD69 and CD163 negative", "M2 macrophage"]}, {"Name": "Introduction", "Colors": ["ffffff", "ff0000"], "Channels": ["DNA", "p53"], "Descriptions": ["Hoechst", "HGSOC has a background TP53 mutation"]}], "Masks": []}
